Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexion switches to solar power

This article was originally published in Scrip

Executive Summary

Alexion Pharmaceuticals has strengthened its green credentials by putting solar panels generating 295kW on the rooftop of its facility in Cheshire, Connecticut, which will provide 9% of its electrical needs. The system was funded by a grant from the Connecticut Clean Energy Fund. The 1,738 photovoltaic cells will reduce its carbon dioxide emissions by 380,000 lbs annually, the company estimates. Alexion markets the appropriately named product Soliris (eculizumab), for the rare and life-threatening blood disorder, paroxysmal nocturnal haemoglobinuria.

You may also be interested in...



Pipeline Watch: Ulcerative Colitis, COVID-19 Clinical Trial Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Synairgen Supercharges R&D With $100m Financing

With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.

Relief Therapeutics/NeuroRx's Aviptadil Promise In COVID-19-Associated Respiratory Failure

Although top-line efficacy results from a small study in critically ill patients with COVID-19 suggest there are therapeutic benefits associated with Relief Therapeutics/NeuroRx’s RLF-100 (aviptadil), further data are awaited from the results of a randomized clinical trial, expected later this year.

Related Companies

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel